創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
19/10/23 GEM118 Suppression of TGF-b/Smad and related signaling Systemic sclerosis Oral Small molecule
Preclinical · Inhibited phosphorylation of Smad3 and expression of Col1a2, FN1 and CTGF stimulated by TGF-b in cultured human dermal fibroblasts.
· Ameliorated bleomycin-induced skin fibrosis in both preventative and curative mouse model.
問合せ
19/10/16 GEM117 Induction of apoptosis in adipocyte Lipolysis, non-surgical fat reduction, Diabetes Refer to Note Small molecule
Phase 2a Route:
Subcutaneous

Note:
· GEM117 specifically induce apoptosis on local injection site adipocyte · Phase 1 showed great safety without drug related SAE in 40 healthy volunteers · In pre-clinical study
- Better efficacy on local fat reduction and less side effects that surpass the current surgical liposuction and other non-surgical products.
- Has benefit effects on lipid and glucose metabolism and improves the indicator of diabetes
問合せ
19/10/16 GEM116 Increase in lipolysis, fat and energy metabolism Obesity, Diabetes, NAFLD/NASH Oral Small molecule
Phase 2 ·GEM116 demonstrated the safest profile in its clinical phase 2 study with more than 200 patients without any drug related AE or SAE and potentially lower CVD risk seen by other competitors in the market
· Around 30% of subjects lost at least 5% body weight in 12 weeks, GEM116 shows around 5% body fat lost, lower TC by around 12mg/dL, and lower LDL by around 6 mg/dL
·Pre-clinical study shows GEM116 has the potential to treat NAFLD/NASH via reducing liver fibrosis by aroud 40% .
問合せ
19/10/16 GEM115 Trastuzumab biosimilar-ADC HER2-positive metastatic breast cancer i.v. Antibody
Phase 1 Conjugate of trastuzumab biosimilar and DM-1. The profiles of trastuzumab of GEM115 and GEM115 are similar to Herceptin and Kadcyla, respectively, in peptide mapping, receptor binding affinity, inhibition of cell proliferation, ADCC activities, in vivo xenograft mouse model, PK etc.
Potential Indication: Early Breast Cancer (adjuvant)
問合せ
19/10/16 GEM114 Ophthalmic formulation of GEM113 wet AMD intra vitreal Antibody
Phase 1 GEM114 mainly distributed in retina, vitreous body and aqueous humor after intravetreal injection in animals.
Potential Indication: Diabetic Macular Edema; Myopic Choroidal Neovascularization (mCNV); Retinal Vein Occlusion (RVO); Diabetic Retinopathy (DR)
問合せ
19/10/16 GEM113 Bevacizumab biosimilar Non-Squamous NSCLC i.v. Antibody
Phase 3 The profile of GEM113 is similar to Avastin, in peptide mapping, receptor binding affinity, inhibition of cell proliferation, in vivo xenograft mouse model, PK etc.
Potential Indication: Metastatic Coloerectal Cancer; Recurrent Giloblastoma; Metastatic Renal Cell Carcinoma; Persistent Recurrent or Metastatic Cervical Cancer; Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
問合せ
19/10/04 GEM065 Refer to Note Refer to Note Infusion Protein
Refer to Note Mechanism of action:
Fucosylation of CAR-T cell and TCR-T cells to improve homing to tumors, increased intra-tumor penetration and killing of cancer cells. Potential for enabling CAR-T cell therapies to achieve higher response rates for treatment of blood cancers and also work for treatment of solid tumors

Indication:
Lymphoma, leukemia, melanoma, lung and breast cancers are initial indications

Development stage:
Preclinical; Human safety and efficacy observed in stem cell transplantation

Note:
Ex-vivo fucosylation kit using proprietary recombinant fucosyl-transferase enzymes aimed at improving efficacy, safety and cost of care for T-cell therapy not only for treatment of blood cancers but also importantly, enabling CAR-T cell therapy to work in the treatment of solid tumors . Similar technology as in GEM036 for hematopoietic stem cell therapy, but a different fucosyl-transferase is used. Fucosylation enhances homing and intra-tumor penetration of CAR-T, TCR-T, TIL/CTL cells for improved tumor killing. Fucosylation does not affect healthy tissues.


問合せ
19/10/04 GEM112 Antibody against H.Pylori-derived HSP60 Eradication of H.Pylori i.v. Protein
Preclinical Antibiotic-resistance H.Pylori are getting serious and antibiotic therapy failure rate is over 20%. GEM112 is a highly specific antibody against H.Pylori-derived HSP60 which inhibits T cell proliferation and induces IL-10 and TGF-b1. GEM112 does not bind to human HSP60. 問合せ
19/09/30 GEM111 c-RAF allosteric inhibitor Refer to Note Oral Small molecule
IND Indication:
Multiple cancers (lung, renal, liver etc)

Note:
A second generation (novel salt) of the c-RAF allosteric inhibitor in GEM 110 allowing for a more patient-centric dose profile. The clinical safety profile of GEM110 thus far will be informative and additive to the current clinical program thereby significantly de-risk and accelerate the clinical stage development of GEM111.
問合せ
19/09/30 GEM110 c-RAF allosteric inhibitor Refer to Note Oral Small molecule
Phase 1 Indication:
Multiple cancers (lung, renal, liver etc)

Note:
The product is the combination of a c-RAF allosteric inhibitor and sorafenib.
The product induces pDAPK and c-Raf to transfer from mitochondria to cytoplasm together with ROS increment resulting tumor cell death and demonstrated 73% and 57% tumor inhibition rate respectively in lung cancer and renal cancer animal xenograft model.
FDA approved the clinical protocol to explore subjects by p-DAPK biomarker whose expressin could be related with tumor progression.
問合せ